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AbstrACt
Introduction In the UK and Ireland, severe and complex 
obesity is managed in specialist weight management 
services (SWMS), which provide multicomponent 
lifestyle interventions to support weight loss, and use of 
medication if available. Liraglutide 3 mg (LIRA 3 mg) is 
an effective weight- loss medication, but weight loss in 
individual patients is variable, and its efficacy has not 
been assessed in SWMS. This study aims to investigate 
whether a targeted prescribing pathway for LIRA 3 mg 
with multiple prespecified stopping rules could help 
people with severe obesity and established complications 
achieve ≥15% weight loss in order to determine whether 
this could be considered a clinically effective and cost- 
effective strategy for managing severe and complex 
obesity in SWMS.
Methods and analysis In this 2- year, multicentre, open- 
label, real- world randomised controlled trial, 384 adults 
with severe and complex obesity (defined as body mass 
index ≥35 kg/m2 plus either prediabetes, type 2 diabetes, 
hypertension or sleep apnoea) will be randomised via a 
2:1 ratio to receive either standard SWMS care (n=128) or 
standard SWMS care plus a targeted prescribing pathway 
for LIRA 3 mg with prespecified stopping rules at 16, 32 
and 52 weeks (n=256).
The primary outcome is to compare the proportion of 
participants achieving a weight loss of ≥15% at 52 weeks 
with a targeted prescribing pathway versus standard 
care. Secondary outcomes include a comparison of (1) the 
weight loss maintenance at 104 weeks and (2) the budget 
impact and cost effectiveness between the two groups in a 
real- world setting.
Ethics and dissemination The Health Research Authority 
and the Medicines and Healthcare products Regulatory 
Authority in UK, the Health Products Regulatory Authority 
in Ireland, the North West Deanery Research Ethics 
Committee (UK) and the St Vincent’s University Hospital 
European Research Ethics Committee (Ireland) have 
approved the study. The findings of the study will be 
published in peer- reviewed journals.
trial registration number  ClinicalTrials. gov—Identifier: 
NCT03036800.
European Clinical Trials Database—Identifier: EudraCT 
Number 2017-002998-20.
IntroduCtIon
Obesity is a complex disease characterised by 
increased hunger and reduced satiety.1 Severe 
and complex obesity is defined as a body mass 
index (BMI) ≥35 kg/m2 with at least one 
major obesity- related complication.2 Around 
10% of the adult population in England has a 
BMI ≥35 kg/m2,3 and many have established 
strengths and limitations of this study
 ► Large, multicentre, real- world, randomised con-
trolled trial.
 ► Assessment of the clinical effectiveness and cost 
effectiveness of a targeted prescribing pathway with 
three stopping rules for liraglutide (LIRA) 3 mg to op-
timise its use in obesity services.
 ► The study will include only patients with severe and 
complex obesity (body mass index ≥35 kg/m2 plus 
either prediabetes, type 2 diabetes, hypertension or 
sleep apnoea) referred to a specialist weight man-
agement service (SWMS).
 ► Some participants will stop using LIRA 3 mg due to 
the second and third stopping rules despite achiev-
ing clinically significant weight loss and metabolic 
benefits.
 ► The study has been deliberately designed as open 
label; however, randomisation to control (standard 
care) group, without the opportunity to receive LIRA 
3 mg, may be a disincentive to adherence to the 
SWMS programme and attendance to study visits 
for some participants.
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complications such as type 2 diabetes (T2D),4 hyperten-
sion5 and sleep apnoea,4 imposing colossal direct and 
indirect healthcare costs.6
Lifestyle interventions are considered cornerstones for 
the management of obesity.7 Despite the impressive results 
from intensive lifestyle interventions in Look Ahead 
study,8 and more recently the Diabetes Remission Clin-
ical Trial (DIRECT) and Counterweight- Plus studies,9 10 
which used intensive and structured weight management 
programmes to achieve weight loss and T2D remission in 
real- life community settings, lifestyle interventions still 
commonly only achieve an average of 5% wt loss11 12 and 
long- term weight maintenance remains a challenge.13 14 
Although weight loss as little as 5% does produce meta-
bolic improvements, it is not enough to make a differ-
ence to the lives of most people with severe and complex 
obesity. Maximal benefits for the treatment of obesity- 
associated complications are obtained with weight loss 
above 15%.15 Pharmacotherapy for obesity can support 
some people to achieve these results,16–18 but currently it 
is not used frequently enough to be considered a corner-
stone treatment.7
Severe and complex obesity is managed in specialist 
weight management services (SWMS) in the UK and 
Ireland.7 11 19 20 SWMS consist of a multidisciplinary team 
typically led by a medical clinician with expertise in obesity 
management and/or a specialist dietician and supported 
by specialist physiotherapists, psychologists and nurses; 
these services offer intensive lifestyle interventions with 
similar components to those used by DIRECT and Look 
Ahead studies, and can be supported by pharmacotherapy.7 
Orlistat is the only weight loss medication approved by the 
National Institute for Health and Care Excellence (NICE) 
for use in SWMS; however, its side effects and limited effec-
tiveness18 21 have reduced the penetrance of its usage. 
SWMS support is usually required for up to 1 year, before 
patients may be offered bariatric surgery.11
Liraglutide 3.0 mg (LIRA 3 mg), a glucagon- like peptide-1 
receptor analogue, was approved in 2015 by the European 
Medicines Agency (EMA) for the treatment of obesity in 
combination with lifestyle intervention after multiple, 
large, phase 3 randomised controlled trials demonstrated 
its safety and efficacy for weight loss, weight maintenance 
and improvement of obesity- related complications.17 22–24
The average weight loss in the Satiety and Clinical 
Adiposity - Liraglutide Evidence (SCALE) Obesity and 
Prediabetes trial at 1 year after initiation of treatment with 
LIRA 3 mg was 8.0%±6.7% compared with 2.6%±5.7% 
for patients in the placebo group.22 The same data also 
suggest that after 1 year of therapy, LIRA 3 mg can result 
in ≥15% wt loss in 14% of patients, compared with 3.5% 
of patients treated with placebo.22 Nevertheless, SCALE 
trials were placebo controlled, included patients with BMI 
as low as 27 kg/m2, and typically combined LIRA 3 mg 
with moderate- intensity lifestyle interventions.17 22–25 These 
limitations make it difficult to predict the clinical effective-
ness of LIRA 3 mg for the treatment of severe and complex 
obesity in SWMS. Addressing these limitations, Wadden et 
al in a pragmatic, single- centre, open- label study demon-
strated that by intensifying the diet and behavioural therapy 
in combination with LIRA 3 mg, 28% of participants were 
able to achieve ≥15% wt loss at 12 months compared with 
12% with intensive behavioural therapy alone.26 There-
fore, the current evidence suggests that LIRA 3 mg could 
help a number of patients with severe and complex obesity 
referred to SWMS to achieve significant weight reduction, 
and this is highly likely to generate substantial health bene-
fits and long- term cost savings, especially if weight loss can 
be maintained, as demonstrated at the 3- year results of the 
SCALE Prediabetes study.25
Currently, LIRA 3 mg has not been approved by NICE 
for use in management of severe and complex obesity in 
the UK. NICE guidelines take into account both the clinical 
and the cost effectiveness of treatment. EMA has approved 
LIRA 3 mg with a single stopping rule of 5% wt loss at 16 
weeks after initiation of treatment, based on a post- hoc 
analysis of the SCALE trials demonstrating that ‘early 
responders’ (defined as those achieved ≥4% wt loss after 
16 weeks of LIRA 3 mg) were more likely to achieve clini-
cally significant weight loss at 1 year compared with ‘early 
non- responders’ (10.8% vs 3.0% mean weight loss in those 
without T2D and 8.5% vs 3.1% mean weight loss in those 
with T2D).27 Based on the EMA single stopping rule, it is 
estimated that 62%–77% of patients with obesity referred 
to SWMS will be suitable to continue long- term on LIRA 
3 mg.27 However, only 9%–21% of those who achieve ≥5% 
wt loss at 16 weeks will obtain maximal benefit (≥15% wt 
loss) from LIRA 3 mg.27 Taking into account the cost of 
the medication, it is unlikely that NICE or other equivalent 
organisations will approve long- term treatment with LIRA 3 
mg for all patients who currently present for obesity treat-
ment in SWMS and achieve the single EMA stopping rule. A 
different and more pragmatic use of LIRA 3 mg in SWMS is 
needed in order for the medication to be targeted to those 
who will benefit most from using it.
In this paper, we describe the rationale and method-
ology of a study investigating the effectiveness and cost of 
a targeted prescribing pathway (with multiple prespecified 
stopping rules) for the use of LIRA 3 mg in SWMS settings 
for treatment of severe and complex obesity. The targeted 
prescribing pathway aims to optimise the use of LIRA 3 mg 
in ‘early responders’ (in accordance with the EMA stopping 
rule) to the combination of lifestyle intervention plus LIRA 
3 mg as well as identifying patients who are most likely to 
benefit more from continued long- term prescription of 
LIRA 3 mg (ie, those who are able to achieve ≥15% wt loss 
at 1 year). This approach aims to direct the use of this medi-
cation to patients with severe and complex obesity that will 
have substantial benefit from it, and at the same time to 
optimise the health economic outcomes (cost effectiveness 
and budget impact of SWMS) associated with the use of 
LIRA 3 mg.
Aim and objectives
The aim of the present study is to compare the clinical 
effectiveness, the cost effectiveness and the budget impact 
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Figure 1 Study design.
(on SWMS) of a targeted prescribing pathway for LIRA 3 
mg (with prespecified stopping rules) plus SWMS stan-
dard care versus the SWMS standard care alone.
The primary objective will be to compare the propor-
tion of participants with severe and complex obesity 
achieving weight loss ≥15% at 52 weeks using a targeted 
prescribing pathway (use of LIRA 3 mg according to a 
prespecified protocol) in combination with SWMS stan-
dard care versus SWMS standard care alone.
The secondary objectives (see also online supplemen-
tary appendix 1) are to compare the targeted prescribing 
pathway plus SWMS standard care versus SWMS standard 
care alone in terms of
1. improving obesity- related complications (prediabetes, 
T2D, hypertension, obstructive sleep apnoea, dyslipi-
daemia, depression) at 52 and 104 weeks.
2. referral rates to other obesity interventions at 52 and 
104 weeks.
3. long- term weight maintenance (defined as the propor-
tion of participants maintaining weight loss of ≥15% at 
104 weeks among those who achieved ≥15% wt loss at 
52 weeks).
4. budget impact on a SWMS at 52 and 104 weeks.
5. estimated cost effectiveness of treatment over 104 
weeks.
6. direct healthcare costs in terms of admissions, frequen-
cy and cost of appointments at 52 and 104 weeks.
7. safety- related outcomes at 52 and 104 weeks.
8. adherence to treatment at 16, 32, 52 and 104 weeks.
9. patient satisfaction and quality of life at 52 and 104 
weeks.
MEthods And AnAlysIs
The protocol of this clinical trial follows the Standard 
Protocol Items: Recommendations for Interventional 
Trials guidelines.28
study design
The current study (Effectiveness and cost of integrating 
a pragmatic pathway for prescribing liraglutide 3.0 mg in 
obesity services (STRIVE study)) is a phase 4, investigator- 
initiated, 2- year, parallel, two group, multicentre, open- 
label, real- world, randomised controlled trial taking place 
in the UK and Ireland. The total duration of participation 
will be 104 weeks (±2 weeks). In total, 384 patients with 
severe and complex obesity who are referred to a SWMS 
will be randomised through a validated online system ( 
sealedenvelope. com) provided through the Leicester 
Clinical Trials Unit (LCTU) in a 2:1 fashion (2 interven-
tion: 1 control) to either the intervention (SWMS stan-
dard care plus targeted prescribing pathway) or control 
arm (SWMS standard care; see also figure 1). Randomi-
sation will be stratified by centre and BMI (>45 kg/m2; 
<45 kg/m2).
The study is intentionally designed to reflect a prag-
matic ‘real- world’ scenario and each SWMS provider may 
require a different number of visits for their programme. 
However, study appointments for data collection, medi-
cation titration reviews, application of the stopping rules 
of LIRA 3 mg and dispensing of the medication will be 
standardised for all of the study sites.
The first 52 weeks of the study will determine whether 
using the targeted prescribing pathway of LIRA 3 mg 
plus standard care in a SWMS setting will result in more 
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participants achieving ≥15% wt loss compared with partic-
ipants in the control group (standard care alone). The 
second 52 weeks of the study will assess whether patients 
who lose ≥15% of their baseline weight by the first 52 
weeks with the targeted prescribing pathway plus standard 
care are more likely to maintain ≥15% wt loss for another 
52 weeks compared with patients in the control group 
(standard care alone) who were also able to achieve ≥15% 
wt loss by the first 52 weeks. Further measurements on 
budget impact of SWMS and cost effectiveness for both 
treatment groups will be assessed and compared.
Control (standard care)
Across the UK and Ireland, each region has a SWMS. 
This service includes a clinician- led multidisciplinary 
team approach, potentially including a specialist physi-
cian, dietitian, nurse, psychologist and physiotherapist/
physical activity physiologist. The accessibility and the 
workflow of the SWMS are broadly similar for all the five 
participating sites in this study.
Participants in the control group will follow the best 
medical care provided by the SWMS at the relevant site. 
This typically involves dietary advice to reduce energy 
intake (and may include a period using formula- diet meal 
replacement or total diet replacement), accompanied—
if available—by a physical activity programme, both 
supported by behavioural change techniques with regular 
professional contacts. The nature of the standard care will 
vary between the different SWMS at each site. Clinician 
input will include the medical assessment of participants 
for severe and complex obesity and the prescription of 
antiobesity drugs (ie, orlistat) as per local SWMS policy. 
Participants will remain in the SWMS in line with NICE 
guidance throughout the duration of the research study. 
Participants may be offered treatment options within the 
duration of the study, including bariatric surgery, as per 
NICE guidance and according to the decision of the local 
SWMS multidisciplinary team.
Intervention (targeted prescribing pathway plus standard 
care)
Participants in the intervention arm will receive the same 
SWMS care with the control arm. Additionally, at base-
line, LIRA 3 mg will be prescribed to all of the partici-
pants in the intervention arm. Dose escalation of LIRA 
will occur in accordance with the summary of product 
characteristics (SPC) from 0.6 mg to a maximum of 3.0 
mg. Participants will be withdrawn from receiving LIRA 3 
mg if the doses are not tolerated during or following the 
titration period.
Participants will also be informed about the prespec-
ified weight loss criteria in order to continue receiving 
treatment with LIRA 3 mg. Participants in the targeted 
prescribing pathway will be prescribed LIRA 3 mg for 
the duration of the study, unless they do not meet the 
predefined weight loss targets at each stopping point 
(after 16, 32 and 52 weeks, see also figure 1).
Targeted prescribing pathway stopping rules
First stopping rule
After 16 weeks (±14 days) on the medication, only those 
participants who have lost ≥5% of their baseline weight 
will be offered further treatment with LIRA 3 mg for 
another 16 weeks.
Second stopping rule
After 32 weeks (±14 days) on the medication, only those 
participants who have lost ≥10% of their baseline weight 
and are still on treatment with LIRA 3 mg will be offered 
another 20 weeks on LIRA 3 mg.
Third stopping rule
After 52 weeks (±14 days) on the medication, only those 
participants who have lost ≥15% of their baseline weight 
and are still on treatment with LIRA 3 mg will be offered 
another 52 weeks on LIRA 3 mg.
Participants who fail to reach the thresholds to 
continue LIRA 3 mg treatment, or who have withdrawn 
from LIRA 3 mg due to intolerance, adverse effects or 
inability to titrate up to a maximum dose of LIRA 3 mg, 
will continue to be offered the standard care provided 
by the relevant SWMS. The conditions for participants’ 
withdrawal from the study as well as for temporary and/
or permanent treatment discontinuation for LIRA 3 mg 
(outside prespecified stopping rules) are described in 
online supplementary appendix 2.
study outcomes
Primary outcome
The primary outcome is the proportion (%) of partici-
pants with severe and complex obesity achieving weight loss 
≥15% of baseline weight at 52 weeks after randomisation 
with the standard care provided in SWMS versus a targeted 
prescribing pathway of LIRA 3 mg with prespecified stop-
ping rules plus the standard care provided in SWMS.
secondary measurements and outcomes
A range of secondary outcomes including anthropomet-
rics, weight maintenance, obesity- associated comorbid-
ities, budget impact, cost effectiveness, safety/adverse 
events, compliance of patients with treatment and refer-
rals to other obesity interventions between the two groups 
will be measured and assessed throughout the study. 
These are listed in online supplementary appendix 1.
study population
Five culturally and racially diverse sites in different 
geographical areas (Dublin, Glasgow, Leicester, Liverpool 
and London) will be used to reflect typical SWMS settings 
across the UK and Ireland.
Potentially eligible patients who have agreed to partici-
pate in the SWMS will be identified by the clinical care team 
and invited for screening. Patients will be allowed at least 
24 hours to consider their participation to the study. Full 
inclusion and exclusion criteria are listed in box 1. Each 
site will plan to recruit up to 77 subjects over the 24- month 
recruitment period.
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box 1 Continued
 ► Current or history of treatment with medications that may cause sig-
nificant weight gain, within 12 weeks prior to randomisation, includ-
ing systemic corticosteroids (except for a short course of treatment, 
that is, 7–10 days), atypical antipsychotic and mood stabilisers (eg, 
clozapine, olanzapine, valproic acid and its derivatives, and lithium)
 ► Initiation of antidepressants during the last 12 weeks
 ► Previous surgical treatment for obesity (excluding liposuction if per-
formed >1 year before trial entry)
 ► History of other severe psychiatric disorders
 ► History of known or suspected abuse of alcohol and/or narcotics
 ► History of major depressive episode during the last 2 years
 ► Simultaneous participation in other clinical trials of investigational 
drugs, lifestyle or physical activity interventions. Patients will only 
be able to take part following participation in a previous clinical trial 
after a wash- out period of 16 weeks.
box 1 Inclusion and exclusion criteria
Inclusion criteria
 ► be aged between 18 and 75 years old (inclusive)
 ► understand written and spoken English
 ► be able to give informed consent
 ► have a body mass index ≥35 kg/m2
 ► have been referred to the specialist weight management service in 
one of the participating sites
 ► have a stable body weight (less than 5 kg self- reported change 
during the previous 12 weeks)
 ► have at least one of prediabetes, type 2 diabetes (T2D), hypertension 
and/or obstructive sleep apnoea, as defined below:
 – prediabetes (defined as established diagnosis of impaired fast-
ing glycaemia from general practitioner (GP) and/or established 
diagnosis of impaired glucose tolerance from GP and/or HbA1C 
42–47 mmol/mol (6%–6.4%) without glucose- lowering medica-
tions, at a blood test during the last 6 months)
 – T2D (defined as established diagnosis of T2D from GP and/or 
HbA1C≥48 mmol/mol (≥6.5%) at a blood test during the last 6 
months and/or being treated with any combination of lifestyle, 
metformin, sulphonylureas, thiazolidinediones or sodium- 
glucose co- tranporter-2 inhibitors)
 – hypertension treated (defined as being on antihypertensive treat-
ment with or without a diagnosis of hypertension from GP) or 
untreated (defined as systolic blood pressure ≥140 mm Hg at two 
consecutive visits at the specialist weight management service 
clinic)
 – obstructive sleep apnoea (on Continuous Positive Airway Pressure 
(CPAP) or established diagnosis of Apnoea Hypopnoea Index≥15 
at sleep studies during the last 12 months).
Exclusion criteria
 ► Diagnosis of type 1 diabetes
 ► T2D with treatment on Dipeptidyl peptidase-4 (DPP-4) inhibitors or 
insulin currently
 ► Treatment with glucagon- like peptide-1 (GLP-1) receptor agonists 
within the last 6 months and/or have a history of GLP-1 receptor 
agonist intolerance.
 ► Treatment with antiobesity drugs within 12 weeks prior to 
randomisation
 ► eGFR ≤30 mL/min/1.73 m2 on serum testing over the last 26 weeks
 ► Females referred to the clinic because of fertility problem
 ► Females of childbearing potential who are pregnant, breast feeding 
or intend to become pregnant or are not using or willing to use ade-
quate contraceptive methods during the study period
 ► Have terminal illness
 ► Are not primarily responsible for their own care
 ► Any other significant disease or disorder, which in the opinion of the 
investigator, may either put the participants at risk or may influence 
the result of the study or the participant’s ability to participate
 ► Untreated or uncontrolled hypothyroidism/hyperthyroidism defined 
as thyroid- stimulating hormone >6 mIU/L or <0.4 mIU/L
 ► Family or personal history of multiple endocrine neoplasia type 2 or 
familial medullary thyroid carcinoma (FMTC)
 ► Personal history of non- FMTC
 ► History of chronic pancreatitis or idiopathic acute pancreatitis
 ► Amylase levels three times higher than the upper normal range
 ► Obesity induced by other endocrinologic disorders (eg, Cushing’s 
Syndrome)
Continued
Figure 2 Participant flowchart. LIRA, liraglutide; SWMS, 
specialist weight management service; WL, weight loss.
study procedures
Study visits
A participant flowchart is demonstrated in figure 2 and 
the study visit outline and measurement plan for each visit 
is included in online supplementary appendix 3, table 1. 
Participants in both groups will attend 13 visits during the 
2- year trial. Participants in the intervention group who 
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continue on LIRA 3 mg during the second year of the study 
will attend two additional visits for safety, monitoring of side 
effects, compliance and medication supply.
screening and consent visit (day −42 to −1)
A study clinician will determine the eligibility of potential 
participants and obtain written informed consent (see 
online supplementary appendix 4). Following this, demo-
graphics, medical and surgical history, anthropometrics 
(height, weight, waist circumference), blood pressure 
and pulse rate, a comprehensive clinical examination 
and routine laboratory investigations will be performed 
(see online supplementary appendix 3, table 1). Female 
participants of childbearing potential will undergo a urine 
pregnancy test. Urine albumin creatinine ratio (ACR) will 
be analysed for participants with prediabetes, T2D and 
hypertension.
All participants will undergo an assessment with the 
King’s College Obesity Staging System (see online supple-
mentary appendix, table 2), STOP- Bang Questionnaire 
and Epworth Sleepiness Score. Participants at risk of undi-
agnosed OSA (defined by STOP- Bang Score of ≥5) will be 
referred to sleep clinic for further investigation. Participants 
with established OSA on CPAP therapy will have their notes 
reviewed to determine compliance with CPAP therapy and 
whether it was a ‘successful’ treatment according to the 
following criteria: (1) CPAP usage ≥4 hours/night=suc-
cessful, (2) CPAP usage <4 hours/night=struggling, and (3) 
CPAP usage ≤1 hour/night=failure.
data collection and safety visits (baseline, weeks 52 and 104)
During the baseline visit, eligibility will be confirmed by the 
study clinician at each site based on the results and inves-
tigations from screening visit. Following this, only eligible 
participants will be randomised and allocated into either 
group (open- label study). Participants allocated to the 
targeted prescribing pathway plus standard care (interven-
tion group) will be prescribed LIRA 3 mg and reminded of 
the prescribing pathway medication stopping rules at weeks 
16, 32 and 52. Participants will receive training to confidently 
administer the Investigational Medical Product. Female 
participants of childbearing potential will be reminded to 
use effective contraception throughout the study.
A full description of the outcome measures and the 
procedures during baseline visit, week 52 and week 104, 
is shown in online supplementary appendix 3, table 1. 
Serious adverse events (SAE) and adverse events (AE) as 
well as changes in medication or diseases will be recorded 
during every visit from consent to the end of study. More-
over, participant adherence to the SWMS programme will 
be monitored (completers will be defined as those who 
attended >70% of scheduled visits in the SWMS during the 
first 52 weeks).
At weeks 52 and 104, blood tests for biochemical 
outcomes will be performed for all participants in the study 
as well as urine ACR for participants with T2D, prediabetes 
and hypertension.
At week 104, the study clinician will evaluate all the 
participants who experience significant weight regain in 
either treatment group and may consider a recommenda-
tion to tier 4 service for bariatric surgery. For ‘responders’ 
on LIRA 3 mg, the clinician will recommend that the 
participant’s GP may consider prescribing LIRA 3 mg 
long term, depending on the local prescribing practice.
Clinical review visits (safety and retention; weeks 2, 4, 8, 12, 
16, 20, 32, 40 and 78)
Participant’s eligibility and consent for continuation in 
the study will be confirmed. Measurements of outcomes 
during these visits including reporting potential AEs/SAEs 
are detailed in online supplementary appendix 3, table 1. 
Participants on LIRA 3 mg will be given advice on dose titra-
tion (at weeks 2 and 4) as per SPC and will be monitored 
for any possible side effects and adherence with the daily 
injection (by examining medication returns).
At week 32, blood tests for biochemical outcomes will 
be performed for all participants in the study as well as 
urine ACR for participants with T2D, prediabetes and 
hypertension.
Additional clinical review (safety and retention) visits for lIrA 
3 mg group (weeks 65 and 91)
Two additional visits will take place only for participants in 
the intervention group who remain eligible and continue 
to be offered treatment with LIRA 3 mg in the second 
year. The visits will be identical to the other clinical review 
visits as described above, with the intention to provide 
participants with a new prescription of LIRA 3 mg, discuss 
adherence with the treatment and record any AE/SAEs.
treatment of trial participants
Study medication
Participants randomised to LIRA 3 mg group will be 
instructed to take daily subcutaneous injection of LIRA 
(Saxenda) while continuing their usual medication. 
Participants will be given specific instructions to adhere 
to the titration policy of LIRA 3 mg in accordance with 
the SpC. LIRA 3 mg will be prescribed to participants for 
a maximum of 106 weeks (4- week dose titration, 100- week 
maintenance dose, ±2- week visit window).
Compliance and accountability: participants will be asked 
to return all unused investigational products and vials/
packages to the pharmacy at each study visit. Compli-
ance and concordance with LIRA 3 mg will be evaluated 
and discussed at each study visit based on tolerability and 
returned vials of medication. Participants will be defined as 
treatment compliant if they self- administer at least 70% of 
planned doses.
harms
Throughout the STRIVE study, all the reported AEs, SAEs 
and other unintended effects of trial interventions or trial 
conduct will be collected, assessed, reported and managed 
according to the Good Clinical Practice—International 
Conference of Harmonisation (GCP- ICH) guidelines.
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data collection, management and confidentiality
Details on data collection, management and confidenti-
ality for the STRIVE study are provided in online supple-
mentary appendix 6.
statistics
Sample size
Based on previous studies, it is anticipated that at 1 year 
approximately 5% of the participants in the standard 
care group will have achieved ≥15% wt loss (likely range: 
3%–5%).17 22 An achievable target for ≥15% wt loss at 
52 weeks in the intervention group (standard care plus 
LIRA 3 mg with prespecified stopping rules) is 16% 
(likely range: 14%–20%).17 22 Accounting for 25% drop 
out, 5% alpha and a 2:1 randomisation ratio with higher 
proportion of participants being randomised to the inter-
vention group; we would need to recruit 384 participants 
(256 intervention group; 128 standard care) to have 
80% power to detect a significant difference between the 
groups in participants achieving ≥15% wt loss at 1 year.
statistical methods and analysis
The primary analysis will compare the proportion of 
participants achieving ≥15% wt loss at 52 weeks (primary 
outcome) after randomisation between the two study 
arms using a logistic regression model with adjustment for 
stratification factors (site and BMI). The adjusted propor-
tion (95% CI) of participants achieving ≥15% wt loss will 
be estimated by group. The primary analysis will be based 
on the complete case population. This is defined as all 
randomised participants who have data available for the 
outcome being analysed, according to the study group to 
which they were randomised at baseline.
The secondary analyses of the primary outcome will be 
based on intention- to- treat (ITT) and per- protocol anal-
yses. The ITT population is defined as all randomised 
participants in the study and the per protocol population is 
defined as all randomised participants who were compliant 
with their treatment group. Treatment compliance for 
the control group is defined as completion at least 70% 
of the planned contacts in the SWMS. Participants in the 
intervention group are defined as treatment compliant 
if they complete at least 70% of the planned contacts in 
the SWMS, and take at least 70% of their planned doses 
of LIRA 3 mg as stipulated by the prescribing pathway. In 
all analyses, participants will be analysed within the treat-
ment arm to which they were allocated at baseline. More 
specifically, participants within the intervention group who 
were taken off LIRA 3 mg due to prespecified stopping 
rule will remain in the intervention group. Participants 
who have undergone bariatric surgery during the first 52 
weeks of the study will be excluded from the complete cases 
population analysis (primary analysis) and the per- protocol 
analysis for the primary outcome (but they will be included 
at the ITT analysis). Missing primary outcome data will be 
imputed for the ITT analyses; categorically, we will classify 
those participants as ‘non- responders’ (did not achieve 
≥15% wt loss at 52 weeks). The characteristics of those with 
missing outcome data will be compared with those who 
have completed follow- up.
Secondary outcomes measured at 52 and 104 weeks 
will be analysed based on the complete cases population. 
Binary outcomes will be analysed using logistic regres-
sion models and summarised using proportion (95% 
CI). Continuous outcomes will be compared using linear 
regression models and summarised as mean with stan-
dard deviation (95% CI). If continuous outcomes are 
non- normally distributed, the most suitable regression 
model will be selected. Only the complete cases popula-
tion will be used for the secondary outcomes to reduce 
the number of models. Participants who have undergone 
bariatric surgery during the first 52 weeks of the study will 
be excluded from the analyses for secondary outcomes 
at 52 weeks. Moreover, participants who have undergone 
bariatric surgery during the study period will be excluded 
from the analyses for secondary outcomes at 104 weeks. 
Data on treatment adherence, safety (including AEs), and 
treatment satisfaction will be summarised and tabulated.
In addition, we will perform a responder analysis which 
will repeat the analyses of the secondary outcomes with 
the intervention group restricted to those participants 
who responded to the targeted prescribing pathway 
(those achieving ≥15% wt loss at 52 weeks after rando-
misation). This allows us to statistically compare the 
outcomes of ‘super’ responders within the targeted 
prescribing pathway to all the participants who received 
standard care in the control group.
health economic input
A state- transition Markov cohort model has been devel-
oped for the cost- effectiveness analysis, with health states 
encompassing the possible comorbidities associated with 
obesity and documented to respond to weight loss. A thor-
ough review of the literature was conducted to identify such 
conditions and inform transition probabilities in the model.
The model projects development of T2DM, myocardial 
infarction, stroke, asthma cancer or mortality in the long 
term (up to lifetime horizon) based on short- term effects 
of interventions in surrogate outcomes—BMI, systolic 
blood pressure, total cholesterol, high- density lipoprotein 
cholesterol and (for patients with T2D) glycated haemo-
globin (HbA1c). Effects on surrogate outcomes are trans-
lated into lifetime risks through risk- prediction models.
Treatment effects are applied incrementally to the effi-
cacy of the targeted prescribing pathway group. Effect on 
weight, in terms of BMI % reduction, is applied at every 
subsequent cycle starting from 3 months after treatment 
start for as long as the cohort remains on treatment and 
over the predefined catch- up time post treatment. Note 
that a natural increase in weight is applied each year to all 
interventions considered, including no treatment.
Treatment can be discontinued at 16 weeks, 32 weeks 
or at 52 weeks (based on the prespecified stopping rule). 
Discontinuation causes the cohort to receive the stan-
dard care provided via the SWMS at the control group. 
Thus, if the discontinuation is allowed at 16 weeks, 
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‘non- responders’ will have the same effect of the cohort 
in the control group, and ‘responders’ will have the effect 
of the targeted prescribing pathway in the clinical trial.
Discontinuation of treatment beyond 52 weeks causes 
BMI, and other cardiometabolic risk factors, to revert 
to the levels projected under the no treatment option. 
Reversal takes place over a given number of cycles (years). 
Costs and quality- of- life outcomes are applied to the 
health state in which the cohort resides at each particular 
moment in time or once off to events. Costs and health 
benefits (life years, quality- adjusted life years, years T2D 
free, years cancer free, etc.) are summed up for the time 
horizon of the model and results reported as incremental 
cost- effectiveness ratios. The risk of acquiring obesity- 
related comorbidities has been taken from published 
epidemiological studies.
Patient and public involvement
Patients and public were not involved in the develop-
ment of the research questions or the design of this study. 
However, on completion of the study, all participants will 
be informed for the results of the study.
EthICs And dIssEMInAtIon
Ethical issues
Approval for the protocol (and any subsequent substan-
tial amendments) has been obtained from the Medi-
cines and Healthcare products Regulatory Agency (UK 
Competent authority) and Health Products Regulatory 
Authority (Irish Competent Authority). This protocol has 
been approved by the Health Research Authority (HRA) 
and ethical approval as a Clinical Trial of an Investiga-
tional Medicinal Product study was granted by the North 
West Deanery National Research Ethics Service (NRES) 
committee (17/NW/0517) in UK (29 September 2017) 
and from the St Vincent’s University Hospital European 
Research Ethics Committee (EUREC) (2017-002998-20) 
in Ireland. This manuscript details the fourth version of 
the protocol approved on 8 June 2018.
The study is conducted in accordance with the prin-
ciples laid down by the 18th World Medical Assembly 
(Helsinki, 1964) and all applicable amendments laid 
down by the World Medical Assemblies, as well as in 
full conformity with the GCP- ICH guidelines (CPMP/
ICH/135/95) July 1996. Ethical and research governance 
approval has been obtained for this study through the 
HRA, appropriate regulatory bodies and National Health 
Service Trust prior to any participant activity.
Protocol amendments
All changes to the study protocol were reviewed by the 
North West Deanery NRES committee in UK and from 
the St Vincent’s Hospital EUREC in Ireland and then 
reported to the sponsor and funder. The participating 
sites and coinvestigators were sent regular emails with 
updates on the study recruitment timeline and any major 
protocol changes during the enrolment period. All signif-
icant protocol changes were noted in  ClinicalTrials. gov.
trial oversight and governance
The study sponsor is the University of Leicester (UK) and 
the study is managed by the LCTU and is overseen by trial 
steering committee (TSC) comprising independent chair 
and a group of experts. This study is registered at the 
http://www. clinicaltrials. gov (NCT03036800) as well as on 
the European Clinical Trials Database (EudraCT Number 
2017-002998-20) before the enrolment of the first partici-
pant and monitored by the University of Leicester.
Safety of the participants will be independently moni-
tored by the Data Monitoring and Ethics Committee, 
which will make recommendations to the TSC for appro-
priate action in the interest of the participants.
Current status and time scale
Recruitment started in November 2017 and the last 
patient last visit should complete by December 2021. To 
date, 380 patients have been screened and consented, of 
which 351 were eligible to participate and 337 have been 
randomised to the study.
dissemination plan
The results of the study will be presented in national and 
international meetings and will be submitted for publi-
cation to the relevant Obesity/General Medical peer- 
reviewed journals. Acknowledgement of any supporting 
organisations, including funders, University of Leicester 
and the LCTU, will be included.
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